<PAGE>
/------------------------------/
/ OMB APPROVAL /
/------------------------------/
/ OMB Number: 3235-0287 /
/ Expires: December 31, 2001 /
/ Estimated average burden /
/ hours per response...... 0.5 /
/------------------------------/
+--------+
| FORM 4 | U.S. SECURITIES AND EXCHANGE COMMISSION
+--------+ WASHINGTON, D.C. 20549
[_] Check this box if
no longer subject STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
to Section 16.
Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities
obligations may Exchange Act of 1934, Section 17(a) of the
continue. See Public Utility Holding Company Act of 1935 or
Instruction 1(b). Section 30(f) of the Investment Company Act of 1940
(Print or Type Responses)
--------------------------------------------------------------------------------
1. Name and Address of Reporting Person
MedEquity Investors, LLC
--------------------------------------------------------------------------------
(Last) (First) (Middle)
Attn: Robert W. Daly
16 Laurel Road, Suite 150
--------------------------------------------------------------------------------
(Street)
Wellesley Hills MA 02481
--------------------------------------------------------------------------------
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol MediChem Life Sciences, Inc. (MCLS)
-----------------------------------
3. I.R.S. or Social Security Number of Reporting Person
(voluntary)
--------------
4. Statement for Month/Year 10/00
---------------------------------------------------
5. If Amendment, Date of Original (Month/Year)
---------------------------------
6. Relationship of Reporting Person(s) to Issuer (Check all applicable)
___ Director ___ Officer _X_ 10% Owner ___ Other
(give title below) (specify below)
----------------------------------------------------------------
7. Individual or Joint/Group Filing (Check Applicable Line)
____ Form filed by One Reporting Person
__X_ Form filed by More than One Reporting Person
Table I--Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
1. Title 2. Trans- 3. Trans- 4. Securities Acquired (A) 5. Amount of 6. Owner- 7. Nature
of action action or Disposed of (D) Securities ship of In-
Security Date Code (Instr. 3, 4 and 5) Beneficially Form: direct
(Instr. 3) (Month/ (Instr. 8) Owned at Direct Bene-
Day/ ----------------------------------------------- End of (D) or ficial
Year) Month Indirect Owner-
Code V Amount (A) or Price (Instr. 3 and 4) (I) ship
(D) (Instr. 4) (Instr. 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Common Stock 10/31/00 J(4) 657,980 A $7.00 6,797,395 I By LLC (1)
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
Table II--Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------
1. Title of Derivative 2. Conver- 3. Trans- 4. Transac- 5. Number of Deriv-
Security (Instr. 3) sion or action tion Code ative Securities
Exercise Date (Instr. 8) Acquired (A) or
Price of (Month/ Disposed of (D)
Deriv- Day/ (Instr. 3, 4, and 5)
ative Year)
Security
---------------------------------------------------
Code V (A) (D)
-----------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
-----------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------
</TABLE>
Table II--Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
6. Date Exer- 7. Title and Amount of 8. Price 9. Number 10. Owner- 11. Na-
cisable and Underlying Securities of of Deriv- ship ture
Expiration (Instr. 3 and 4) Deriv- ative Form of In-
Date ative Secur- of De- direct
(Month/Day/ Secur- ities rivative Bene-
Year) ity Bene- Security: ficial
(Instr. ficially Direct (D) Owner-
-------------------------------------------- 5) Owned or Indirect ship
Date Expira- Amount or at End (I) (Instr.
Exer- tion Title Number of of (Instr. 4) 4)
cisable Date Shares Month
(Instr. 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
Additional Reporting Persons for the Acquisitions of the Common Stock of
MediChem Life Sciences, Inc. (MCLS)
<TABLE>
<CAPTION>
Amount of
Name and Address of Designated Transaction Transaction Securities
Reporting Person Reporter (2) Date Code Acquired Price
------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Robert W. Daly MedEquity 10/31/00 J(4) 657,980 $7.00
MedEquity Investors, LLC Investors,
16 Laurel Road, Suite 150 LLC
Wellesley Hills, MA 02481
------------------------------------------------------------------------------------------------------------
ChaseMedichem Partners, LLC MedEquity 10/31/00 J(4) 390,244 $7.00
Attn: Robert W. Daly Investors,
16 Laurel Road, Suite 150 LLC
Wellesley Hills, MA 02481
------------------------------------------------------------------------------------------------------------
Peachtree Medichem Partners, LLC MedEquity 10/31/00 J(4) 226,706 $7.00
Attn: Robert W. Daly Investors,
16 Laurel Road, Suite 150 LLC
Wellesley Hills, MA 02481
------------------------------------------------------------------------------------------------------------
</TABLE>
<TABLE>
<CAPTION>
Amount of Securities Ownership Form: Nature of Indirect
Name and Address of Beneficially Owned Direct (D) or Beneficial
Reporting Person at End of Month Indirect (I) Ownership
------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Robert W. Daly 6,797,395 I (3)
MedEquity Investors, LLC
16 Laurel Road, Suite 150
Wellesley Hills, MA 02481
------------------------------------------------------------------------------------------------------------
ChaseMedichem Partners, LLC 4,031,497 D N.A.
Attn: Robert W. Daly
16 Laurel Road, Suite 150
Wellesley Hills, MA 02481
------------------------------------------------------------------------------------------------------------
Peachtree Medichem Partners, LLC 2,342,028 D N.A.
Attn: Robert W. Daly
16 Laurel Road, Suite 150
Wellesley Hills, MA 02481
------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
Explanation of Responses:
(1) MedEquity Investors, LLC is the Managing Member of ChaseMedichem Partners,
LLC and Peachtree Medichem Partners, LLC, and an affiliate of MedEquity
Investors Partners, LLC (the "LLC Shareholders"), which in the aggregate
hold 6,797,395 shares of Common Stock following the acquisition of 657,980
shares disclosed in this statement.
(2) The Designated Reporter is executing this report on behalf of itself,
Peachtree Medichem Partners, LLC and ChaseMedichem Partners, LLC.
(3) Mr. Daly is the Managing Member of MedEquity Investors, LLC, which may be
deemed the beneficial owner of 6,797,395 shares (see Note 1). Mr. Daly
disclaims beneficial ownership of such shares, except to the extent of his
pecuniary interest.
(4) In connection with the closing of the initial public offering (the "IPO")
of MediChem Life Sciences, Inc. ("MCLS"), the LLC Shareholders purchased
from the underwriters an aggregate of 657,980 shares of Common Stock at the
IPO price of $7.00 per share.
MedEquity Investors, LLC
/s/ Robert W. Daly November 13, 2000
------------------------------- ------------------
**Signature of Reporting Person Date
/s/ Robert W. Daly November 13, 2000
------------------------------- ------------------
Robert W. Daly Date
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
If the form is filed by more than one reporting person, see
Instruction 4(b)(v).
Potential persons who are to respond to the collection of information
contained in this form are not required to respond unless the form
displays a current valid OMB Number.
** Intentional misstatements or omissions of facts constitute Federal
Criminal Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed.
If space is insufficient, see Instruction 6 for procedure.
